Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Evaluation of Clinical Efficacy
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Aletaha, D.; Smolen, J.S. The rheumatoid arthritis patient in the clinic: Comparing more than 1300 consecutive DMARD courses. Rheumatology 2002, 41, 1367–1374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Al Saleh, J.; Ragab, G.; Nash, P.; Halabi, H.; Laatar, A.; El-Sayed Yousef, A.M.; Ehsouna, H.; Hammoudeh, M. Rheumatoid arthritis in the Middle East and Africa: Are we any closer to optimising its management? Clin. Rheumatol. 2015, 34, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smolen, J.S.; Aletaha, D.; Machold, K.P. Therapeutic strategies in early rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2005, 19, 163–177. [Google Scholar] [CrossRef] [PubMed]
- Bannwarth, B.; Labat, L.; Moride, Y.; Schaeverbeke, T. Methotrexate in rheumatoid arthritis. An update. Drugs 1994, 47, 25–50. [Google Scholar] [CrossRef]
- Cronstein, B.N. Going with the flow: Methotrexate, adenosine, and blood flow. Ann. Rheum. Dis. 2006, 65, 421–422. [Google Scholar] [CrossRef]
- Cutolo, M.; Sulli, A.; Pizzorni, C.; Seriolo, B.; Straub, R.H. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 2001, 60, 729–735. [Google Scholar] [CrossRef] [Green Version]
- Świerkot, J.; Szechiński, J. Methotrexate in rheumatoid arthritis. Pharmacol. Rep. 2006, 58, 473–492. [Google Scholar]
- Drouin, J.; Haraoui, B. Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy. J. Rheumatol. 2010, 37, 1405–1410. [Google Scholar] [CrossRef]
- Smolen, J.S.; Landewé, R.; Breedveld, F.C.; Dougados, M.; Emery, P.; Gaujoux-Viala, C.; Gorter, S.; Knevel, R.; Nam, J.; Schoels, M.; et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 2010, 69, 964–975. [Google Scholar] [CrossRef] [Green Version]
- Romão, V.C.; Lima, A.; Bernardes, M.; Canhão, H.; Fonseca, J.E. Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity? Immunol. Res. 2014, 60, 289–310. [Google Scholar] [CrossRef]
- Anderson, J.J.; Wells, G.; Verhoeven, A.C.; Felson, D.T. Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration. Arthritis Rheum. 2000, 43, 22–29. [Google Scholar] [CrossRef]
- Emery, P.; Bingham, C.O., 3rd; Burmester, G.R.; Bykerk, V.P.; Furst, D.E.; Mariette, X.; van der Heijde, D.; van Vollenhoven, R.; Arendt, C.; Mountian, I.; et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann. Rheum. Dis. 2017, 76, 96–104. [Google Scholar] [CrossRef]
- Forslind, K.; Hafström, I.; Ahlmén, M.; Svensson, B.; BARFOT Study Group. Sex: A major predictor of remission in early rheumatoid arthritis? Ann. Rheum. Dis. 2007, 66, 46–52. [Google Scholar] [CrossRef] [Green Version]
- Smolen, J.S.; Strand, V.; Koenig, A.S.; Szumski, A.; Kotak, S.; Jones, T.V. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res. Ther. 2016, 18, 114. [Google Scholar] [CrossRef] [Green Version]
- Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., III; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 2010, 69, 1580–1588. [Google Scholar] [CrossRef]
- Fuchs, H.A.; Brooks, R.H.; Callahan, L.F.; Pincus, T. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum. 1989, 32, 531–537. [Google Scholar] [CrossRef]
- Majorczyk, E.; Pawlik, A.; Gendosz, D.; Kuśnierczyk, P. Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment. BMC Musculoskelet Disord. 2014, 15, 256. [Google Scholar] [CrossRef] [Green Version]
- Bianchi, G.; Caporali, R.; Todoerti, M.; Mattana, P. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration. Adv. Ther. 2016, 33, 369–378. [Google Scholar] [CrossRef] [Green Version]
- Aggarwal, R.; Liao, K.; Nair, R.; Ringold, S.; Costenbader, K.H. Anti-Citrullinated Peptide Antibody (ACPA) Assays and their Role in the Diagnosis of Rheumatoid Arthritis. Arthritis Rheum. 2009, 61, 1472–1483. [Google Scholar] [CrossRef] [Green Version]
- Daha, N.A.; Toes, R.E.M. Rheumatoid arthritis: Are ACPA-positive and ACPA-negative RA the same disease? Nat. Rev. Rheumatol. 2011, 7, 202–203. [Google Scholar] [CrossRef]
- Liao, K.P.; Weinblatt, M.E.; Solomon, D.H. The end of rheumatoid factor as we know it? Arthritis Rheum. 2011, 63, 1170–1172. [Google Scholar] [CrossRef]
- Romão, V.C.; Canhão, H.; Fonseca, J.E. Old drugs, old problems: Where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Med. 2013, 11, 17. [Google Scholar] [CrossRef] [Green Version]
- de Moel, E.C.; Derksen, V.F.A.M.; Trouw, L.A.; Bang, H.; Collée, G.; Lard, L.R.; Ramiro, S.; Huizinga, T.W.J.; Allaart, C.F.; Toes, R.E.M.; et al. In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Res. Ther. 2019, 21, 28. [Google Scholar] [CrossRef] [Green Version]
- Lequerre, T.; Jouen, F.; Brazier, M.; Clayssens, S.; Klemmer, N.; Menard, J.-F.; Mejjad, O.; Daragon, A.; Tron, F.; Loët, X.L.; et al. Autoantibodies, metaloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology 2007, 46, 446–453. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maillefert, J.F.; Puéchal, X.; Falgarone, G.; Lizard, G.; Ornetti, P.; Solau, E.; Legré, V.; Lioté, F.; Sibilia, J.; Morel, J.; et al. Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. Jt. Bone Spine 2010, 77, 558–563. [Google Scholar] [CrossRef] [PubMed]
- Wunderlich, C.; Oliviera, I.; Figueiredo, C.P.; Rech, J.; Schett, G. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis. Semin Arthritis Rheum. 2017, 46, 709–714. [Google Scholar] [CrossRef] [PubMed]
- Lukas, C.; Mary, J.; Debandt, M.; Daïen, C.; Morel, J.; Cantagrel, A.; Fautrel, B.; Combe, B. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: Data from the ESPOIR cohort. Arthritis Res. Ther. 2019, 21, 243. [Google Scholar] [CrossRef] [Green Version]
- Aletaha, D.; Funovits, J.; Keystone, E.C.; Smolen, J.S. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007, 56, 3226–3235. [Google Scholar] [CrossRef]
- Sherrer, Y.S.; Bloch, D.A.; Mitchell, D.M.; Roth, S.H.; Wolfe, F.; Fries, J.F. Disability in rheumatoid arthritis: Comparison of prognostic factors across three populations. J. Rheumatol. 1987, 14, 705–709. [Google Scholar]
- Weinblatt, M.E.; Keystone, E.C.; Cohen, M.D.; Freundlich, B.; Li, J.; Chon, Y.; Baumgartner, S.W. Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate. J. Rheumatol. 2011, 38, 242–246. [Google Scholar] [CrossRef]
- Smolen, J.S.; van der Heijde, D.M.F.M.; St. Clair, E.W.; Emery, P.; Bathon, J.M.; Keystone, E.; Maini, R.N.; Kalden, J.R.; Schiff, M.; Baker, D.; et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis Rheum. 2006, 54, 702–710. [Google Scholar] [CrossRef]
- Wessels, J.A.M.; van der Kooij, S.M.; le Cessie, S.; Kievit, W.; Barerra, P.; Allaart, C.F.; Huizinga, T.W.J.; Guchelaar, H.-J.; Pharmacogenetics Collaborative Research Group. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007, 56, 1765–1775. [Google Scholar] [CrossRef]
- Saevarsdottir, S.; Wallin, H.; Seddighzadeh, M.; Ernestam, S.; Geborek, P.; Petersson, I.F.; Bratt, J.; van Vollenhoven, R.F.; SWEFOT Trial Investigators Group. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: Results from the initial open-label phase of the SWEFOT trial. Ann. Rheum. Dis. 2011, 70, 469–475. [Google Scholar] [CrossRef]
- Hoekstra, M.; van Ede, A.E.; Haagsma, C.J.; van de Laar, M.A.F.J.; Huizinga, T.W.J.; Kruijsen, M.W.M.; Laan, R.F.J.M. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2003, 62, 423–426. [Google Scholar] [CrossRef]
- Sokka, T.; Toloza, S.; Cutolo, M.; Kautiainen, H.; Makinen, H.; Gogus, F.; Skakic, V.; Badsha, H.; Peets, T.; Baranauskaite, A.; et al. Women, men, and rheumatoid arthritis: Analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res. Ther. 2009, 11, R7. [Google Scholar]
- Kvien, T.K.; Uhlig, T.; Ødegård, S.; Heiberg, M.S. Epidemiological aspects of rheumatoid arthritis: The sex ratio. Ann. N. Y. Acad. Sci. 2006, 1069, 212–222. [Google Scholar] [CrossRef]
- Tedeschi, S.K.; Bermas, B.; Costenbader, K.H. Sexual disparities in the incidence and course of SLE and RA. Clin. Immunol. 2013, 149, 211–218. [Google Scholar] [CrossRef]
- Lesuis, N.; Befrits, R.; Nyberg, F.; van Vollenhoven, R.F. Gender and the treatment of immune-mediated chronic inflammatory diseases: Rheumatoid arthritis, inflammatory bowel disease and psoriasis: An observational study. BMC Med. 2012, 10, 82. [Google Scholar] [CrossRef]
- Sokka, T.; Hetland, M.L.; Mäkinen, H.; Kautiainen, H. Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. Arthritis. Rheum. 2008, 58, 2642–2651. [Google Scholar] [CrossRef]
Parameters | |
---|---|
Female sex | 253 |
Male sex | 59 |
Age (years) | 58.0 ± 12.7 |
Age at disease onset (years) | 48.0 ± 13.1 |
Disease duration (years) | 10.0 ± 8.8 |
ESR (mm/h) | 40.42 ± 24.61 |
RF+ | 208 |
CCP+ | 193 |
Vasculitis | 56 |
Sicca syndrome | 24 |
Amyloidosis | 14 |
Groups | Age (Mean ± SD) | Disease Duration (Mean ± SD) | Age at Onset (Mean ± SD) | ESR (mm/h) (Mean ± SD) |
---|---|---|---|---|
Good responders | 59.4 ± 12.4 | 9.0 ± 7.3 | 50.4 ± 12.3 | 27.3 ± 18.75 |
Poor responders | 56.1 ± 12.9 | 11.3 ± 10.0 | 44.9 ± 13.5 | 58.1 ± 39.47 |
p | 0.32 | 0.27 | 0.0001 | <0.0001 |
Remission (%) | Patients Subgroup | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Female Sex | Male Sex | RF+ | RF− | ED+ | ED− | CCP+ | CCP− | Extra+ | Limited | RF+ | RF− | |
to | ED+ | ED− | ||||||||||
Joints | Extra+ | Extra− | ||||||||||
n-253 | n-59 | n-208 | n-104 | n-231 | n-81 | n-193 | n-119 | n-94 | n-218 | n-54 | n-34 | |
Good response | 56.5 | 61.0 | 47.1 | 77.9 | 49.8 | 77.8 | 53.9 | 57.1 | 44.7 | 62.8 | 29.6 | 88.2 |
Poor response | 43.5 | 39.0 | 52.9 | 22.1 | 50.2 | 22.3 | 46.1 | 42.9 | 55.3 | 37.2 | 70.4 | 11.8 |
p value # | 0.65 | <0.0001 | <0.0001 | 0.61 | 0.003 | <0.0001 | ||||||
OR | 0.83 | 0.25 | 0.28 | 0.87 | 0.48 | 0.06 | ||||||
95%CI | 0.47–1.48 | 0.15–0.43 | 0.16–0.51 | 0.55–1.39 | 0.29–0.78 | 0.02–0.19 |
Independent Variables | OR | 95%CI | p-Value |
---|---|---|---|
Age at disease diagnosis | 1.055 | 1.023–1.086 | 0.0007 |
Log(ESR) * | 0.020 | 0.009–0.056 | <0.0001 |
ED | 0.417 | 0.163–0.974 | 0.042 |
RF | 0.316 | 0.148–0.736 | 0.006 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Majorczyk, E.; Mazurek-Mochol, M.; Pawlik, A.; Kuśnierczyk, P. Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate. J. Clin. Med. 2022, 11, 6078. https://doi.org/10.3390/jcm11206078
Majorczyk E, Mazurek-Mochol M, Pawlik A, Kuśnierczyk P. Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate. Journal of Clinical Medicine. 2022; 11(20):6078. https://doi.org/10.3390/jcm11206078
Chicago/Turabian StyleMajorczyk, Edyta, Małgorzata Mazurek-Mochol, Andrzej Pawlik, and Piotr Kuśnierczyk. 2022. "Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate" Journal of Clinical Medicine 11, no. 20: 6078. https://doi.org/10.3390/jcm11206078
APA StyleMajorczyk, E., Mazurek-Mochol, M., Pawlik, A., & Kuśnierczyk, P. (2022). Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate. Journal of Clinical Medicine, 11(20), 6078. https://doi.org/10.3390/jcm11206078